214 related articles for article (PubMed ID: 29525393)
1. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.
Floege J; Tsirtsonis K; Iles J; Drueke TB; Chertow GM; Parfrey P
Kidney Int; 2018 Jun; 93(6):1475-1482. PubMed ID: 29525393
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
[TBL] [Abstract][Full Text] [Related]
3. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.
Louie KS; Erhard C; Wheeler DC; Stenvinkel P; Fouqueray B; Floege J
J Nephrol; 2020 Aug; 33(4):803-816. PubMed ID: 31848883
[TBL] [Abstract][Full Text] [Related]
5. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation.
Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994
[TBL] [Abstract][Full Text] [Related]
6. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
8. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
10. [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
Zwiech R; Chrul S
Wiad Lek; 2012; 65(3):145-50. PubMed ID: 23289260
[TBL] [Abstract][Full Text] [Related]
11. Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic-pharmacodynamic analysis of cinacalcet.
Chen P; Sohn W; Narayanan A; Gisleskog PO; Melhem M
Br J Clin Pharmacol; 2019 Jun; 85(6):1312-1325. PubMed ID: 30756425
[TBL] [Abstract][Full Text] [Related]
12. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
14. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.
Wheeler DC; London GM; Parfrey PS; Block GA; Correa-Rotter R; Dehmel B; Drüeke TB; Floege J; Kubo Y; Mahaffey KW; Goodman WG; Moe SM; Trotman ML; Abdalla S; Chertow GM; Herzog CA;
J Am Heart Assoc; 2014 Nov; 3(6):e001363. PubMed ID: 25404192
[TBL] [Abstract][Full Text] [Related]
15. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
Akizawa T; Shimazaki R; Fukagawa M;
PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Parfrey PS; Drüeke TB; Block GA; Correa-Rotter R; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Kubo Y; Dehmel B; Goodman WG; Chertow GM;
Clin J Am Soc Nephrol; 2015 May; 10(5):791-9. PubMed ID: 25710802
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
[TBL] [Abstract][Full Text] [Related]
18. Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Otsuka K; Ohno Y; Oshima J
Ren Fail; 2018 Nov; 40(1):38-42. PubMed ID: 29301445
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Floege J; Kubo Y; Floege A; Chertow GM; Parfrey PS
Clin J Am Soc Nephrol; 2015 May; 10(5):800-7. PubMed ID: 25887067
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
